(Total Views: 341)
Posted On: 10/09/2019 1:39:18 PM
Post# of 154854
Summary
Recent milestone: first injection in TNBC trial; MOA
First five patients with positive results might suffice
Comparison with HUMIRA and KEYTRUDA
For combo (small indication), BP might not be that interested; mono generates much more interest.
Need to get to revenue. In negotiations with mid-tier pharmas; licensing out sales.
If other indications work out, CYDY might become one of the top bio-companies of the world.
Need another 10m or 15m more to get to year-end. Multiple catalysts and milestones ahead (PrEP, BLA submission etc.). Multiple choices for that funding; not going to accept low price for any deal, have capability of rasing funds needed on our own. Licensing out (90m deal) is very well alive, great situaion, can't wait to announce what will become of it.
Recent milestone: first injection in TNBC trial; MOA
First five patients with positive results might suffice
Comparison with HUMIRA and KEYTRUDA
For combo (small indication), BP might not be that interested; mono generates much more interest.
Need to get to revenue. In negotiations with mid-tier pharmas; licensing out sales.
If other indications work out, CYDY might become one of the top bio-companies of the world.
Need another 10m or 15m more to get to year-end. Multiple catalysts and milestones ahead (PrEP, BLA submission etc.). Multiple choices for that funding; not going to accept low price for any deal, have capability of rasing funds needed on our own. Licensing out (90m deal) is very well alive, great situaion, can't wait to announce what will become of it.
(2)
(0)
